萨吉梅生物科学
SGMT
8.02
-0.15
-1.84%
萨吉梅生物科学
US · SGMT
#3599 按市值排名
上市于 2023
8.02
-0.15
-1.84%
实时 - 追踪5344个代码 - 心跳于2秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了10.9个百分点。
机构持股
- 机构持股比例
- 74.39% -10.94pp
- 机构数量
- 138
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund34.04%
Mutual Fund29.09%
VC/PE Fund6.21%
Public Company4.43%
Individual/Insider0.96%
Private Company0.23%
Insurance Company0.18%
Government Pension Fund0.10%
Endowment Fund0.10%
Other24.66%
主要股东 截至 2026-06-30
BlackRock
9.27% · 6.58M 股
Balyasny Asset Management L.P.
5.11% · 3.63M 股
Woodline Partners LP
4.23% · 3.00M 股
Vanguard Capital Management, LLC
4.18% · 2.97M 股
Silverarc Capital Management, LLC
4.13% · 2.93M 股
Caligan Partners, LP
3.53% · 2.50M 股
BVF Partners L.P.
3.53% · 2.50M 股
Affinity Asset Advisors, LLC
3.52% · 2.50M 股
Federated Hermes, Inc.
2.94% · 2.09M 股
Great Point Partners, LLC
2.86% · 2.03M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 13次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| David Happel | Chief Executive Officer | 0.52% |
| Beth Seidenberg | Independent Director | 0.19% |
| Elizabeth Rozek | Chief Compliance Officer | 0.14% |
| Eduardo Martins | Chief Medical Officer | 0.05% |
| George Kemble | Executive Chairperson | 0.03% |
| Merdad Parsey | Independent Director | 0.02% |
| Thierry Chauche | Chief Financial Officer | 0.00% |
| Timothy Walbert | Director | 0.00% |
| Elizabeth Grammer | Independent Director | -- |
| Anne Phillips | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-13 | George Kemble | Executive Chairperson | Derivative Exercise and Sale | -350,987 | $6.36–10.23 |
| 2026-08-10 | George Kemble | Executive Chairperson | Derivative Exercise and Sale | -20,206 | $6.36–9.95 |
| 2026-07-19 | George Kemble | Executive Chairperson | Automatic Disposition | -18,844 | $7.46 |
| 2026-07-19 | David Happel | Chief Executive Officer | Open Market Disposition | -64,051 | $7.76 |
| 2026-07-19 | Elizabeth Rozek | Chief Compliance Officer | Open Market Disposition | -10,545 | $7.76 |
| 2026-06-11 | Beth Seidenberg | Independent Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Elizabeth Grammer | Independent Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | George Kemble | Executive Chairperson | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Anne Phillips | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Paul Hoelscher | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-06-11 | Jennifer Jarrett | Director | Other Derivative Acquisition | +39,567 | $6.48 |
| 2026-05-27 | David Happel | Chief Executive Officer | Other Derivative Acquisition | +300,000 | $7.27 |
| 2026-05-27 | Elizabeth Rozek | Chief Compliance Officer | Other Derivative Acquisition | +100,000 | $7.27 |
| 2026-05-27 | Andreas Grauer | Chief Medical Officer | Other Derivative Acquisition | +35,000 | $7.27 |
| 2026-05-27 | Thierry Chauche | Chief Financial Officer | Other Derivative Acquisition | +50,000 | $7.27 |
| 2026-04-19 | Andreas Grauer | Chief Medical Officer | Other Derivative Acquisition | +264,759 | $6.44 |
| 2026-02-18 | Eduardo Martins | Chief Medical Officer | Other Acquisition | +44,000 | -- |
| 2026-02-18 | Eduardo Martins | Chief Medical Officer | Other Derivative Acquisition | +88,000 | $5.38 |
| 2026-02-18 | David Happel | Chief Executive Officer | Other Acquisition | +128,000 | -- |
| 2026-02-18 | David Happel | Chief Executive Officer | Other Derivative Acquisition | +256,000 | $5.38 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:19 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
萨吉梅生物科学 讨论区 0 条评论